Clinical Trials

The purpose of this study is to assess the efficacy and safety of pembrolizumab (Keytruda) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.
More details

This trial will investigate if using an immunotherapy drug alone prior to the combination of immunotherapy and standard chemotherapy is safe and effective in treating breast cancer before surgery.
More details

This study looks at anti-HER2 therapy plus endocrine therapy with or without palbociclib in patients with hormone receptor-positive HER2+ metastatic breast cancer. This study aims to extend the time before the disease progresses.
More details

The aim of the POSNOC trial is to find out if further axillary treatment is of benefit in women with macrometastases found in one or two lymph nodes.
More details

This phase 3 study will evaluate the efficacy and safety of GDC-0077 in combination with palbociclib and fulvestrant in patients with PIK3CA-mutant, ER+, HER2-negative locally advanced or metastatic breast cancer.
More details

A randomised clinical trial of adjuvant radiation therapy versus observation following breast conserving surgery and endocrine therapy in patients with molecularly characterised luminal A low risk early breast cancer.
More details

This phase 2 clinical trial is looking into lymph node grafting for upper limb lymphoedema following breast cancer treatment.
More details

The New Zealand Familial Breast Cancer Study commenced in 2013 with the key goal of better-understanding DNA sequence changes in genes that alter the risk of developing breast cancer 
More details

The PantoCIN trial will test the ability of a cheap, widely available drug to prevent two of chemotherapy’s most unpleasant side-effects: delayed nausea and vomiting.
More details

A study assessing the safety and effectiveness of Q-122 for treating hot flushes, in women who have, or have had, breast cancer.
More details

THYmine2 is an observational study to assess whether the thymine loading test can prospectively categorize patients who cannot tolerate 5-FU treatment (e.g. FOLFOX, CapeOx, FLOX). This treatment is commonly used in breast cancer treatment. Reactions occur in approximately 10% of patients and can result in life-threatening events.
More details

The primary purpose of this study is to investigate whether it is effective and feasible to treat post cancer related fatigue (CRF) using acupuncture.
More details

The primary purpose of this study is to develop and evaluate a new low literacy decision aid relating to fertility preservation for younger women with early stage breast cancer.
More details

This study will determine whether SAR439859 per os improves progression free survival (PFS) when compared with a endocrine monotherapy of the choice of the physician, in participants with metastatic or locally advanced breast cancer.
More details

The purpose of this study is to examine the action of a new medication (called “(Z)-endoxifen”) in patients with breast cancer.
More details

This is a proof-of-concept pilot study to determine if short-term treatment with denosumab (trade names Prolia and Xgeva) is a feasible chemoprevention option against breast cancer for BRCA1 and BRCA2 mutation carriers.
More details

BRCA-P is an international breast cancer prevention clinical trial open to women with a confirmed BRCA1 gene mutation who have not had a diagnosis of breast cancer.
More details

A study assessing the efficacy and safety of capivasertib + fulvestrant versus placebo + fulvestrant as treatment for locally advanced or metastatic HR+/HER2- breast cancer following recurrence or progression on or after treatment with an aromatase inhibitor
More details

A study of neoadjuvant nivolumab + palbociclib + anastrozole in post-menopausal women and men with primary breast cancer.
More details

A study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk ER+, HER2- early stage breast cancer.
More details

This study aims to assess the efficacy and safety of cryotherapy in preventing CIPN in patients receiving taxanes for breast or gynaecological cancer.
More details

This study will investigate the use of tesetaxel in patients with taxane-naïve, HER2-, HR+ locally advanced or metastatic breast cancer.
More details

This study aims to find out if the combination of anti-HER2 therapy with PD-L1 inhibitor and CTLA4 inhibitor will reactivate anti-tumour immune response and improve clinical outcomes in trastuzumab-resistant, advanced HER2+ breast cancer.
More details

This study is testing olaparib, in homologous recombination (HR) deficient metastatic breast cancer in patients who do not have hereditary mutations in BRCA1 and BRCA2.
More details

This study will determine whether treatment with alpelisib in combination with abraxane is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation or have PTEN loss without PIK3CA mutation.
More details

The primary purpose of this study is to compare the efficacy of denosumab treatment with placebo in preventing bone decay in premenopausal women being treated with ovarian suppression and aromatase inhibition for breast cancer.
More details

The purpose of this study is to see if a handheld imaging device (MEprobe) can accurately detect the microscopic presence of cancer in breast surgery patients.
More details

A study that aims to identify how anthracycline chemotherapy affects exercise capacity and risk of functional disability, and whether exercise training during and following chemotherapy is helpful in protecting against functional disability.
More details

The purpose of this research study is to implement and evaluate a neurotoxicity-targeted intervention during chemotherapy for breast cancer.
More details

This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of GDC-9545 in participants with Stage I-III operable ER+, HER2- untreated breast cancer.
More details

This study will evaluate the safety and pharmacokinetics of ipatasertib in combination with palbociclib and fulvestrant to identify a dose of ipatasertib that can be combined with palbociclib and fulvestrant in the Phase III portion.
More details

Lifepool is a research resource for study into breast cancer and women's health. It aims to recruit 100,000 Australian women. This will establish one of the largest cohorts in the world, providing research tools to answer critical questions about breast cancer. Lifepool aims to gather information on health and lifestyle, mammogram data and asks permission to track the health of each participant through linkage with other health databases.
More details

A phase 2 study of local therapy (stereotactic radiosurgery and/or surgery) for treatment of up to five brain metastases from HER2 positive breast cancer.
More details

This study will see if the study drug LY3484356 alone or in combination with abemaciclib is safe and effective in participants with advanced or metastatic breast cancer.
More details

This study is investigating the safety, tolerability and pharmacokinetic (PK) profile of LYT-100 in healthy volunteers and in those with breast cancer-related lymphoedema.
More details

This study aims to evaluate the long term cardiovascular risk factors associated with taking endocrine therapies in patients with oestrogen receptor positive breast cancer.
More details

This study is investigating the combination of palbociclib, letrozole and venetoclax in ER and BCL-2 positive locally advanced or metastatic breast cancer.
More details

This interventional study will look at the effect of self-directed physical activity and motivational interviewing on quality of life, psychological health and immune outcomes in female breast cancer survivors
More details

The purpose of this study is to determine whether a structured peer support program can improve exercise adherence and health outcomes in breast cancer survivors.
More details

This study aims to find out if women with locally advanced breast cancer can have breast conserving surgery instead of mastectomy with a low chance of the cancer returning.
More details

This study aims to generate new knowledge on the feasibility and effectiveness of pre-operative exercise training to induce clinically relevant improvements in physical fitness in patients with breast cancer undergoing surgery in the Grampians region of Victoria, Australia.
More details

This dose escalation and expansion study will investigate the use of spartalizumab + LAG525 in combination with NIR178, capmatinib, MCS110, or canakinumab in patients with advanced or metastatic triple negative breast cancer.
More details

A study to evaluate the safety and tolerability of immunotherapy combinations in participants with advanced malignancies
More details

This is an open-label, multicenter, global phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3 or ROS1 gene fusion.
More details

This study aims to help researchers understand if receiving a text message support program during the COVID-19 pandemic supports people who have completed active breast cancer treatment.
More details

This study aims to assess the impact of a computerised cognitive training program on the neurotoxic effects of chemotherapy on cognition in breast cancer patients.
More details

The purpose of this study is to determine if breast cancer genetic material (known as circulating tumour DNA (ctDNA) can be detected in the bloodstream. It is hoped that this research will demonstrate the utility of this circulating material as an early marker of residual or recurrent breast cancer activity after treatment
More details

An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer.
More details